Breast Cancer ESMO 2024 Highlights

home / data-dialogue-with-the-oncology-brothers / breast-cancer-esmo-2024-highlights

Rahul Gosain, MD; Rohit Gosain, MD, and Paolo Tarantino, MD, analyze recent oncology trial results presented at ESMO 2024, focusing on primary endpoints, survival outcomes, and progression-free survival data across multiple studies including NATALEE, KEYNOTE-522, and DESTINYBreast-12.

EP. 1: Key Highlights From NATALEE at ESMO 2024

Rahul Gosain, MD;Rohit Gosain, MD;Paolo Tarantino, MD

September 26th 2024

Panelists discuss how the NATALEE study at ESMO 2024 presented updates on primary, secondary, and exploratory end points for evaluating a new cancer treatment.

EP. 2: KEYNOTE-522 Update From ESMO 2024

Rahul Gosain, MD;Rohit Gosain, MD;Paolo Tarantino, MD

September 26th 2024

Panelists discuss how updates from KEYNOTE-522 at ESMO 2024 revealed important data on overall survival and event-free survival outcomes.

EP. 3: ESMO 2024: DESTINY-Breast12 Updates

Rahul Gosain, MD;Rohit Gosain, MD;Paolo Tarantino, MD

September 26th 2024

Panelists discuss how ESMO 2024 presented important updates on primary end points and progression-free survival data from recent clinical studies.